亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns

克拉斯 肺癌 医学 内科学 肿瘤科 中止 癌症 癌症研究 生物信息学 生物 结直肠癌
作者
Jessica Lee,Russell William Madison,Anthony Classon,Ole V. Gjoerup,Mark Richard Rosenzweig,Garrett Michael Frampton,Brian Michael Alexander,Geoffrey R. Oxnard,Jeffrey Michael Venstrom,Mark Magdi Awad,Alexa Betzig Schrock
出处
期刊:JCO precision oncology [Lippincott Williams & Wilkins]
卷期号:5 (5): 1354-1376 被引量:52
标识
DOI:10.1200/po.21.00122
摘要

PURPOSE MET exon 14 ( METex14) skipping alterations are oncogenic drivers in non–small-cell lung cancer (NSCLC). We present a comprehensive overview of METex14 samples from 1,592 patients with NSCLC, associated clinicogenomic characteristics, potential mechanisms of acquired resistance, treatment patterns, and outcomes to MET inhibitors. METHODS Hybrid capture–based comprehensive genomic profiling (CGP) was performed on samples from 69,219 patients with NSCLC. For treatment patterns and outcomes analysis, patients with advanced METex14-altered NSCLC were selected from the Flatiron Health-Foundation Medicine clinicogenomic database, a nationwide deidentified electronic health record–derived database linked to Foundation Medicine CGP for patients treated between January 2011 and March 2020. RESULTS A total of 1,592 patients with NSCLC (2.3%) were identified with 1,599 METex14 alterations spanning multiple functional sites (1,458 of 60,244 tissue samples and 134 of 8,975 liquid samples). Low tumor mutational burden and high programmed death ligand 1 expression were enriched in METex14-altered samples. MDM2, CDK4, and MET coamplifications and TP53 mutations were present in 34%, 19%, 11%, and 42% of tissue samples, respectively. Comparing tissue and liquid cohorts, coalteration frequency and acquired resistance mechanisms, including multiple MET mutations, EGFR, ERBB2, KRAS, and PI3K pathway alterations, were generally similar. Positive percent agreement with the tissue was 100% for METex14 pairs collected within 1 year (n = 7). Treatment patterns showed increasing adoption of MET inhibitors in METex14-altered NSCLC after receipt of CGP results; the real-world response rate to MET inhibitors was 45%, and time to treatment discontinuation was 4.4 months. CONCLUSION Diverse METex14 alterations were present in 2%-3% of NSCLC cases. Tissue and liquid comparisons showed high concordance and similar coalteration profiles. Characterizing common co-occurring alterations and immunotherapy biomarkers, including those present before or acquired after treatment, may be critical for predicting responses to MET inhibitors and informing rational combination strategies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ChenYQ完成签到,获得积分10
6秒前
苹果完成签到 ,获得积分10
13秒前
殷勤的半凡完成签到,获得积分10
34秒前
耍酷的手套完成签到,获得积分10
38秒前
44秒前
49秒前
充电宝的应助被爱学习的doge采纳,获得10
49秒前
49秒前
49秒前
49秒前
orixero的应助被爱学习的doge采纳,获得10
49秒前
隐形曼青的应助被爱学习的doge采纳,获得10
49秒前
在水一方的应助被爱学习的doge采纳,获得10
49秒前
大模型的应助被爱学习的doge采纳,获得10
49秒前
华仔的应助被爱学习的doge采纳,获得10
49秒前
香蕉觅云的应助被爱学习的doge采纳,获得10
56秒前
CodeCraft的应助被爱学习的doge采纳,获得10
56秒前
SciGPT的应助被爱学习的doge采纳,获得10
56秒前
隐形曼青的应助被爱学习的doge采纳,获得10
56秒前
小二郎的应助被爱学习的doge采纳,获得10
56秒前
852的应助被爱学习的doge采纳,获得10
56秒前
56秒前
田様的应助被爱学习的doge采纳,获得10
56秒前
脑洞疼的应助被爱学习的doge采纳,获得10
57秒前
bkagyin的应助被爱学习的doge采纳,获得10
57秒前
顺利水桃完成签到,获得积分10
58秒前
1分钟前
乐乐的应助被mengdewen采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918